{"id":23833,"date":"2025-05-15T13:30:41","date_gmt":"2025-05-15T06:30:41","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=23833"},"modified":"2025-05-15T13:30:41","modified_gmt":"2025-05-15T06:30:41","slug":"anbio-biotechnology-to-showcase-global-diagnostic-innovations-at-three-major-may-exhibitions","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=23833","title":{"rendered":"Anbio Biotechnology to Showcase Global Diagnostic Innovations at Three Major May Exhibitions"},"content":{"rendered":"<p><i><span>\u2014 Accelerating Expansion Across Human and Veterinary Health Through Innovation and Strategic Collaboration<\/span><\/i><\/p>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">BRUSSELS<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">May 15, 2025<\/span><\/span> \/PRNewswire\/ <span>&#8212;<\/span> Anbio Biotechnology, a global leader in in-vitro diagnostic (IVD) technologies, is pleased to announce its participation in three major international exhibitions this May: EuroMedLab 2025 in <span class=\"xn-location\">Brussels<\/span>, AVA Conference 2025 in <span class=\"xn-location\">Sydney<\/span>, and the 47th ACMTT 2025 in <span class=\"xn-location\">Bangkok<\/span>. These events reflect Anbio&#8217;s strategic commitment to expanding its global footprint across human and animal healthcare, building new partnerships, and sharing its vision for accessible, high-performance diagnostics.<\/p>\n<p>As healthcare systems around the world seek faster, more accurate, and <span>decentralized<\/span> testing solutions, Anbio is well-positioned to meet this demand through a diversified portfolio and expanding global network.<\/p>\n<p><i>&#8220;These exhibitions are not just product showcases\u2014they represent Anbio&#8217;s mission to reshape diagnostics through collaboration, innovation, and accessibility,&#8221; said <span class=\"xn-person\">Michael Lau<\/span>, CEO of Anbio Biotechnology. &#8220;We look forward to connecting with partners and professionals who share our vision of smarter, more inclusive healthcare.&#8221;<\/i><\/p>\n<p>At all three exhibitions, Anbio will feature its comprehensive diagnostic portfolio designed to meet the needs of both clinical and veterinary professionals. Key solutions include:<\/p>\n<ul type=\"disc\">\n<li><b>Fluorescence Immunoassay (FIA) Systems: <\/b>Supports 90 test items, offering rapid and quantitative detection across a broad range of clinical areas\u2014including cardiac markers, hormones, infectious diseases, inflammation, tumor markers and others.<\/li>\n<li><b>Dry Chemistry Analyzers: <\/b>Compact and user-friendly systems designed for essential biochemical testing at the point of care. Utilizing independent test strip-based reagents, offers a simpler, maintenance-free testing experience\u2014ideal for <span>decentralized<\/span> settings such as community clinics, mobile units, and veterinary practices.<\/li>\n<li><b>Rapid Test Kits: <\/b>Lateral flow and immunoassay-based kits for on-site diagnostics\u3002<\/li>\n<li><b>Molecular Diagnostic System:<\/b> Offers a versatile molecular diagnostics portfolio, including LAMP-based Rapid Mdx System, and real-time RT-PCR reagents. With room temperature-stable reagents and streamlined protocols, these solutions enable faster, more accessible nucleic acid detection.<\/li>\n<li><b>Veterinary Diagnostics Suite: <\/b>Provides a comprehensive diagnostic solution for veterinarians, integrating immunoassays, biochemical testing, and molecular diagnostics. This all-in-one approach supports accurate, efficient, and on-site decision-making for a wide range of companion animal health needs.<\/li>\n<\/ul>\n<p>These innovations are built on a shared foundation of accuracy, speed, and usability, enabling deployment in hospitals, labs, mobile units, veterinary clinics, and remote field settings.<\/p>\n<p><b>Global Vision, Local Action<\/b><\/p>\n<p>With product registrations in over 100 countries and a growing network of international partners, Anbio continues to pursue a global strategy of innovation, collaboration, and commercialization. Its participation in EuroMedLab, AVA, and ACMTT underscores a commitment to engaging with local markets while driving global standards.<\/p>\n<p>As part of this initiative, Anbio is actively seeking distribution partners, research collaborators, and strategic investors to expand diagnostic access and co-develop market-specific solutions.<\/p>\n<p><b>About Anbio Biotechnology<\/b><\/p>\n<p>Anbio Biotechnology is a globally oriented IVD company focused on empowering healthcare professionals through innovative diagnostic solutions. Its portfolio spans immunofluorescence, dry chemistry, chemiluminescence, molecular diagnostics, and rapid testing. With strong R&amp;D capabilities and a presence in over 100 countries, Anbio is dedicated to building a healthier world through diagnostics that are fast, accurate, and accessible to all.<\/p>\n<p>For more information about the Anbio Biotechnology, follow us on social media for the latest news and updates.<\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<p><i><span>\u2014 Accelerating Expansion Across Human and Veterinary Health Through Innovation and Strategic Collaboration<\/span><\/i><\/p>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">BRUSSELS<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">May 15, 2025<\/span><\/span> \/PRNewswire\/ <span>&#8212;<\/span> Anbio Biotechnology, a global leader in in-vitro diagnostic (IVD) technologies, is pleased to announce its participation in three major international exhibitions this May: EuroMedLab 2025 in <span class=\"xn-location\">Brussels<\/span>, AVA Conference 2025 in <span class=\"xn-location\">Sydney<\/span>, and the 47th ACMTT 2025 in <span class=\"xn-location\">Bangkok<\/span>. These events reflect Anbio&#8217;s strategic commitment to expanding its global footprint across human and animal healthcare, building new partnerships, and sharing its vision for accessible, high-performance diagnostics.<\/p>\n<p>As healthcare systems around the world seek faster, more accurate, and <span>decentralized<\/span> testing solutions, Anbio is well-positioned to meet this demand through a diversified portfolio and expanding global network.<\/p>\n<p><i>&#8220;These exhibitions are not just product showcases\u2014they represent Anbio&#8217;s mission to reshape diagnostics through collaboration, innovation, and accessibility,&#8221; said <span class=\"xn-person\">Michael Lau<\/span>, CEO of Anbio Biotechnology. &#8220;We look forward to connecting with partners and professionals who share our vision of smarter, more inclusive healthcare.&#8221;<\/i><\/p>\n<p>At all three exhibitions, Anbio will feature its comprehensive diagnostic portfolio designed to meet the needs of both clinical and veterinary professionals. Key solutions include:<\/p>\n<ul type=\"disc\">\n<li><b>Fluorescence Immunoassay (FIA) Systems: <\/b>Supports 90 test items, offering rapid and quantitative detection across a broad range of clinical areas\u2014including cardiac markers, hormones, infectious diseases, inflammation, tumor markers and others.<\/li>\n<li><b>Dry Chemistry Analyzers: <\/b>Compact and user-friendly systems designed for essential biochemical testing at the point of care. Utilizing independent test strip-based reagents, offers a simpler, maintenance-free testing experience\u2014ideal for <span>decentralized<\/span> settings such as community clinics, mobile units, and veterinary practices.<\/li>\n<li><b>Rapid Test Kits: <\/b>Lateral flow and immunoassay-based kits for on-site diagnostics\u3002<\/li>\n<li><b>Molecular Diagnostic System:<\/b> Offers a versatile molecular diagnostics portfolio, including LAMP-based Rapid Mdx System, and real-time RT-PCR reagents. With room temperature-stable reagents and streamlined protocols, these solutions enable faster, more accessible nucleic acid detection.<\/li>\n<li><b>Veterinary Diagnostics Suite: <\/b>Provides a comprehensive diagnostic solution for veterinarians, integrating immunoassays, biochemical testing, and molecular diagnostics. This all-in-one approach supports accurate, efficient, and on-site decision-making for a wide range of companion animal health needs.<\/li>\n<\/ul>\n<p>These innovations are built on a shared foundation of accuracy, speed, and usability, enabling deployment in hospitals, labs, mobile units, veterinary clinics, and remote field settings.<\/p>\n<p><b>Global Vision, Local Action<\/b><\/p>\n<p>With product registrations in over 100 countries and a growing network of international partners, Anbio continues to pursue a global strategy of innovation, collaboration, and commercialization. Its participation in EuroMedLab, AVA, and ACMTT underscores a commitment to engaging with local markets while driving global standards.<\/p>\n<p>As part of this initiative, Anbio is actively seeking distribution partners, research collaborators, and strategic investors to expand diagnostic access and co-develop market-specific solutions.<\/p>\n<p><b>About Anbio Biotechnology<\/b><\/p>\n<p>Anbio Biotechnology is a globally oriented IVD company focused on empowering healthcare professionals through innovative diagnostic solutions. Its portfolio spans immunofluorescence, dry chemistry, chemiluminescence, molecular diagnostics, and rapid testing. With strong R&amp;D capabilities and a presence in over 100 countries, Anbio is dedicated to building a healthier world through diagnostics that are fast, accurate, and accessible to all.<\/p>\n<p>For more information about the Anbio Biotechnology, follow us on social media for the latest news and updates.<\/p>\n<p><!-- \/wp:html --><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-23833","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/23833","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=23833"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/23833\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=23833"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=23833"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=23833"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}